Diabetes: T1DM and lipid-lowering therapies

Indicator

The percentage of patients with type 1 diabetes aged over 40 years (excluding people with a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy.

Resource impact

The previous indicator IND166 was as follows:

The percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin.

Indicator IND277 updates and replaces IND166 and expands the lipid-lowering therapies in the indicator beyond statins.

In NICE’s guideline on cardiovascular disease, atorvastatin is recommended for the primary and secondary prevention of cardiovascular disease in adults with type 1 diabetes. Alternative lipid-lowering therapies may be considered if statins are contraindicated or not tolerated, or cholesterol treatment targets are not met.

This indicator therefore widens the lipid-lowering therapies in the indicator and is not expected to lead to a significant change in clinical practice. Any associated resource impact is therefore unlikely to be significant.